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Advances in molecular biology have generated methods that are used to enhance diagnosis and treatment of a variety of 
human diseases. More recently, modification of gene expression i cells by gene transfer has been introduced as a new 
therapeutic modality. The targeting of vascular cells with this method is appealing not only for anatomical reasons, but also 
because ndovascular techniques provide access to the vasculature and makes ite-specific delivery possible. Over the past 
few years, gene transfer has been widely used to explore the pathophysiology of vascular diseases in experimental models 
and available data suggests that this method may eventually become a therapeutic alternative for vascular disorders uch 
as restenosis, graft failure, and critical ischaemia. In the following, we discuss the methodology of gene transfer, its tentative 
use in vascular diseases related to vascular surgery, and the problems associated with this new technology. 
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Introduction 
Manipulation of the genome in cells of living organ- 
isms can be used to study the role of specific genes in 
vivo. In vascular biology, this strategy involves the 
identification, or cloning, of a gene encoding a protein 
with a presumed function in a physiological process 
or disease of the vessel wall. The gene can be inserted 
into a vector, for example a viral plasmid, and 
transferred into cells of the vessel wall where the 
protein is secreted and the biological effects studied 
(Fig. 1). 1 This strategy exemplifies how gene expres- 
sion can be manipulated in a tissue compartment and 
is also the basis of gene therapy. 
Initiall)~ it was predicted, and feared that gene 
therapy would be employed in correcting genetic 
defects in the genome of germ cells. Today, the method 
involves genetic modification ofsomatic ells only and 
is not associated with a manipulation ofthe genome of 
germ cells that can be carried on from one generation 
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to the other, a Gene therapy can be defined as the 
transfer of genetic material to prevent or treat a 
disease. The first gene therapy attempted in humans 
was performed in 1990, and aimed to correct the 
congenital immune defect adenosine deaminase defi- 
ciency (ADA). 3 The promising results of this and other 
attempts initiated more than 100 clinical gene therapy 
trials throughout the world. In the U.S., these trials are 
dominated by anti-cancer therapies followed by trials 
dealing with genetic disorders, diagnostics, AIDS and 
cardiovascular disease. 4 So far the technology is at its 
infancy and safe and effective gene therapy in humans 
has not yet been convincingly demonstrated. 5'6 
Studies in animal models imply that there is a 
therapeutic potential of gene therapy in cardiovas- 
cular disease. Introduction of genes into vascular cells 
of animals has been used as methods to explore the 
functions of genes in the vessel wall and in attempts to 
treat vascular disorders. Here, we discuss how results 
from these animal studies may translate into the 
future use of gene therapy in disease states related to 
vascular surgery such as restenosis, critical limb 
ischaemia, and graft failure. 
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Principles of Gene Transfer 
Gene transfer is defined as the introduction of foreign 
DNA into somatic ells. The first step in this process is 
to isolate the gene that encodes the protein of interest. 
This is done by extracting mRNA from cultured cells 
and converting the mRNA into DNA by reverse 
transcription. This mixture of DNA, called a eDNA 
librar~ is thereafter screened to identify the eDNA 
fragment that matches the amino acid sequence of the 
desired protein. The fragment is thereafter inserted 
into a plasmid expression vector and linked to a 
sequence, a promoter, that initiates transcription of the 
gene (Fig. 1). 7 
Cells do not naturally take up foreign DNA and the 
transfer of DNA into the host cell is a major problem. 
Transfer can be accomplished by physical methods 
(direct ransfer) or by the use of carrier (vector) of viral 
or chemical origin. 7 The chosen mode of transfer 
should be efficient, provide a stable transcription of 
the incorporated DNA, and be reasonably safe. 8 Viral 
vectors have a high transfer efficiency (the percentage 
of cells expressing the desired protein) whereas the 
transfer efficiency of non-viral vectors is usually less 
than 1%. There is a growing concern regarding the 
safety of viral vectors and new non-viral transfer 
methods with improved efficiency are being devel- 
oped. The mode of action of the transferred gene may 
also determine the necessary transfer efficiency. If a 
protein is to act intracellularly, more cells have to be 
transfected than if the protein is to be secreted. 9'1° 
After successful transfer of foreign DNA into the host 
cell, the inserted DNA may be designed to (1) replace 
a missing or defective gene, (2) over-express a protein 
resulting in a local pharmacological effect (gene 
augmentation) or (3) inhibit host cell gene expression 
(antisense gene therapy). 
Physical delivery 
DNA can be transferred into cells and tissues directly 
by injection or other physical delivery methods. 
Injection of DNA into tissues has been successfully 
used in gene transfer of myocardium and skeletal 
muscle. ~1'12 The method is safe, but the transfer 
efficiency is low since naked DNA is only taken up by 
a small number of cells in the target tissue. 1 Despite 
this disadvantage, physical delivery was chosen as the 
mode of transfer in the first approved human trial for 
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Fig. 1. Examination f gene function in vivo using a gene transfer protocol. (1) After isolation and cloning of the gene of interest, (3) the gene 
(eDNA), is ligated into a plasmid expression vector together with a promoter that initiates transcription ofthe gene. (4) The plasmid is 
introduced into the target cells using either physical, viral, or chemical transfer. (5) The gene is transcribed and the desired protein expressed 
locally by endothelial ceils (ECs) or smooth muscle cells (SMCs) in the vessel wall. The protein may exert its effects either within or outside 
the transfected cells. 
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vascular gene therapy. 13 In this stud3~ DNA encoding 
the endothelium specific mitogen, vascular endothe- 
lial growth factor (VEGF), is delivered to the luminal 
endothelial cells (ECs) by diffusion from a hydrogel 
coat of an angioplasty balloon. 14 Since the transferred 
DNA is not incorporated into the host cell genome, it 
will not be replicated in the cell cycle. The duration of 
gene expression is therefore limited and the method is 
suitable only when a transient effect of the therapy is 
desired. 
Viral vectors 
The ability of viruses to infect cells is the basis for the 
use of viral vectors in the transfer of DNA. Virus 
particles contain a protein coat surrounding the 
genetic information, either in the form of RNA or 
DNA. The virus particle binds to sites on the cell 
membrane, the nucleic acid is released into the 
cytoplasm, and translocates to the nucleus. Retro- 
viruses contain a genetic code of RNA which, when 
introduced into the cytoplasm, is converted into DNA 
by a viral enzyme called reverse transcriptase. 15 In 
order to utilise retroviruses as vectors, the virus is 
made replication incompetent by deleting the genes 
required for viral replication. The infection of cells 
with a foreign gene will therefore result in incorpora- 
tion and expression of this gene but no production of 
new viral particles. 16 The introduced DNA is incorpo- 
rated into the host genome where it is replicated in 
each cell cycle. Although this process permanently 
alters the host cell genome and allows a stable 
expression of the foreign gene over a long period of 
time, the method is not effective unless the DNA is 
incorporated into the genome of replicating cells. 17 
Thus, it is difficult to predict he efficacy of retroviral 
transfer in tissues with a slow turnover of cells, such 
as the endothelium and the intima of atherosclerotic 
vessels. Because the transfer efficiency with retroviral 
vectors is so poor in vivo, this method has mainly been 
used in cell-mediated or ex vivo gene transfer. Cells are 
isolated from an individual, subjected to retroviral 
transfection i vitro and the cells secreting the desired 
protein are again implanted back into the individual. 
This method was used to transfect myoblasts that 
were implanted into skeletal muscle of humans with 
Duchenne's muscular dystrophy. 18 In animals it has 
been used to transfer genes to autologous cells before 
seeding onto vascular grafts, 19'2° or into injured 
arteriesY -23 The major advantage of this method is a 
stable long term expression of the introduced 
genes, 22'23 but the low transfer efficiency in vivo limits 
the use to cell-mediated transfer. 24 In addition, the 
safety of retroviral vectors is questioned, especially 
regarding mutations at sites of gene insertion in the 
host genome, and possible generation of replication 
competent viruses. 25 
Adenoviruses contain a double-stranded DNA gen- 
ome and infect cells by binding to cell surface 
receptors which after internalisation, translocates to 
the nucleus. The viral genome and the introduced 
gene will be transcribed separately from the host 
chromatin as an episome. This DNA is not replicated 
along with the host genome which limits the duration 
of expression. As with retroviral vectors, adenoviral 
vectors are made replication defective and the foreign 
gene is incorporated into the viral genome using 
packaging cell lines. 26'27 It has been difficult to 
engineer adenoviral vectors lacking expression of viral 
proteins which generates problems with immune 
responses towards the infected host cell. It was 
recently shown that transfer of replication-defective 
adenoviral vectors into normal arteries in rabbits was 
accompanied by an inflammatory response in the 
vessel wall and associated intimal hyperplasia. 28In 
contrast o other viral and chemical vectors, adeno- 
viruses are very efficient and promote effective gene 
transfer of vascular cells after both intravenous and 
intra-arterial administration. 26 However, atheroscle- 
rotic vessels appear to be less susceptible to adenoviral 
gene transfer compared with normal arteries. 29'3° The 
major disadvantages with adenoviral vectors is the 
immune response and questionable safety regarding 
cytotoxicity and potential transfection of germ cells 
(Fig. 2). 
Chemical vectors 
These methods utilise chemical solutions to facilitate 
DNA delivery into the host cell. Liposomes are 
chemically engineered particles of a lipid bilayer 
which spontaneously form a lipophilic coat around 
DNA plasmids. Upon fusion with the cell membrane, 
the foreign DNA is translocated to the nucleus where 
it is transcribed extrachromosomally, similar to adeno- 
viral vectors. 31 In contrast o adenoviruses, liposomal 
vectors are safe and do not elicit an immunological 
response in the host. However, the transfer efficiency 
is low and the duration of gene expression is limited. 32 
Modification of liposomes by conjugation with the 
Sendai virus, Hemagghitinin Virus of Japan (HVJ- 
liposomes), enhances binding of liposomes to the cell 
surface and increases the transfer efficiency. 33 
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Endovascular Delivery Devices 
Advances in endovascular technology has intersected 
those of molecular medicine and the technique has 
been useful in the transfer of DNA into cells of the 
vessel wall. 34-36 Most catheter systems are derived 
from the conventional Gruentzig angioplasty balloon 
catheter. This may be of advantage since drug or gene 
delivery can be combined with angioplasty proce- 
dures. 35'36 In the double balloon system, the vessel is 
occluded by two sequential balloons and blood flow 
redirected through a central channel. Here, drugs or 
genes can be delivered in the compartment created by 
the two balloons and the system has been used in both 
animals and humans. 37'38 Because infusion can be 
done with minimal pressure, vessel wall damage is 
reduced and the method is useful in targeting drugs to 
ECs. Other systems are based on a combination of 
angioplasty and drug infusion into the vessel wall. 
The porous balloon developed by Wolinsky and 
Thung s9 delivers the infusate into the vessel wall 
through perforations in a single lumen balloon cathe- 
ter. The technique allows fast delivery and minimal 
leaking of agents. However, the perfusion pressure is 
critical and may cause injury to the vessel wall. These 
side effects may be reduced with smaller pores, 
microporous balloons, or channel balloons where the 
drug is delivered through side channels at a low 
pressure outside of the angioplasty balloon. 4°'41 The 
hydrogel balloon has a coat of hydrophilic polacryl 
acid polymer outside a regular balloon in which the 
drug is embedded. The drug will here diffuse into the 
vessel wall as the balloon is inflated and pressed 
against he endothelium. The method is limited to 
situations when a small vessel segment is the target 
since the drug will rapidly diffuse from the hydrogel 
when exposed to the blood stream. To conclude, this 
supply of devices demonstrates the progress and 
ingenuity of endovascular technolog~ and it seems 
reasonable to predict that the technique will be 
optimised to suit the chosen therapy (Fig. 3). 
Gene Therapy in the Treatment of Restenosis 
Reconstruction of atherosclerotic arteries by angio- 
plasty, endarterectomy, or bypass surgery causes 
vessel injury and induces a healing response in the 
vessel wall that may lead to luminal narrowing and 
occlusion of the reconstructed segment. For the past 15 
years, the problem of restenosis and vein graft stenosis 
has been a major challenge for cardiovascular 
research. Despite significant progress in the under- 
standing of the pathophysiology of vascular epair in 
animal models, no pharmacological therapy is availa- 
ble for humans. 
Intimal hyperplasia has long been regarded as the 
principal cause of restenosis. This process has been 
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Fig. 2. Principles of gene transfer using viruses or liposomes. (A) The gene inserted into a plasmid, recombinant DNA, is incorporated into 
viral particles using a packaging cell ine. The viral particle infects the host cell by cell surface binding and endocytosis, and the plasmid 
is thereafter translocated to the nucleus. (B) Liposomes are mixed with, and form a lipid bilayer around the recombinant DNA. These fuse 
with the plasma membrane and releases the DNA into the cytoplasm. 
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extensively characterised in animal models and is 
defined as a fibroproliferative response to trauma 
within the vessel wall intima. Because similar histopa- 
thological features are found in human lesions, it has 
been assumed that this is also a central event in lesion 
development in humans. In the most commonly used 
animal model for intimal hyperplasia, balloon denu- 
dation of the rat common carotid artery is followed by 
platelet aggregation and simultaneously, an activation 
of smooth muscle cells (SMCs) is observed in the inner 
parts of media. A few days later, DNA-synthesis can 
be detected in the media and migration of SMCs from 
the media to the intima is observed 4 days after the 
injury. In the intima, further proliferation of SMCs 
takes place along with the deposition of extracellular 
matrix and together this results in the formation of a 
neointima. 42,43 
Gene transfer experiments have been used to 
investigate mechanisms involved in the development 
of intimal hyperplasia nd in experiments designed to 
interfere with this process. 1 In general, SMC prolifera- 
tion has been the pathophysiological process targeted 
with the therapy. Inhibition of gene expression central 
to SMC proliferation has been achieved by antisense 
gene therapy where the transferred DNA is designed 
to inhibit the expression of a specific host cell gene. 44 
Targeting of proto-oncogenes such as the early 
response genes c-myc and c-myb, 4~47 or genes 
involved in cell cycle control with antisense have been 
shown to suppress intimal proliferation of SMCs in 
different animal models. 48"49 Because antisense DNA 
partly lack specificity, the use of this therapy may be 
limited in a clinical setting. 5° Other central events in 
SMC proliferation can be approached using gene 
augmentation. Inhibition of post-angioplasty intimal 
hyperplasia was obtained both in rat and porcine 
arteries after adenoviral transfer and over-expression 
of the retinoblastoma gene (Rb), an endogenous 
inhibitor of cell-cycle progression. 51The same effect 
was achieved after adenoviral transfection of herpes 
virus thymidine-kinase into injured porcine artery 
segments. 52 Here, the antiproliferative ffect was 
obtained by systemic administration of ganciclovir. 
This drug is not toxic for normal SMCs, but in cells 
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Fig. 3. Examples of modified angioplasty balloons designed to be used for local delivery of drugs or genesinto cells of the vascular wall. 
(A) Double balloon catheter: the agent is infused into a closed compartment in between the balloons and can diffuse with minimal pressure 
into the vessel wall. (B) Perforated balloon: the agent is infused u der pressure through pores in the balloon wall and into the vessel tissue. 
(C) Hydrogel coated balloon: The agent is mixed in the hydrogel which dissolves in the blood stream when the balloon is inflated and 
pressed against the vessel wall. The agent can th  diffuse into the luminal cells. 
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transfected with herpes virus thymidine kinase, it is 
converted into a toxic compound which terminates 
DNA-synthesis and restricts the hyperplastic response 
after injury. 
Anti-proliferative gene therapy may also inhibit re- 
endothelialisation of denuded vessels. Since ECs 
suppress SMC growth, inhibition of re-endothelialisa- 
tion may counteract the desired effect. The growth- 
inhibitory properties of ECs can instead be used as an 
alternative anti-proliferative approach. Although the 
mechanisms whereby ECs influence SMC growth are 
not clear, the association between re-endothelialisation 
of an injured vessel and the cessation of SMC 
replication within the intima has been known for a 
long t ime9 This growth inhibition may be mediated 
by nitric oxide (NO), produced by these cells due to a 
constitutive xpression of endothelial constitutive NO 
synthase (ecNOS). 54 In vivo transfection of the ecNOS 
gene in the rat carotid balloon angioplasty model was 
recently found to restrict SMC proliferation and 
intimal hyperplasia9 5 Similar results have been 
obtained after balloon denudation in animal models 
by local administration ofNO donors and by restoring 
the endothelium using recombinant endothelial 
growth factors such as VEGF, acidic- and basic 
fibroblast growth factor (a- and bFGF). 56-61 
Although available data from animal studies have 
suggested that the proliferation of SMCs should be a 
suitable therapeutic target in the management of 
human restenosis, the use of this strategy in clinical 
trials with conventional drugs has been disappoint- 
ing. 62 This paradox may have several explanations. 
Many human trials have not been performed with a 
study design equivalent o the experimental situa- 
tion. 63-64 In addition, the restenosis process in a 
human, atherosclerotic, vessel is probably not compa- 
rable to the generation of intimal hyperplasia fter 
injury of a non-diseased artery in an atherosclerosis- 
resistant species, 65'55 and more appropriate animal 
models have to be developedF In contrast o animal 
lesions, examinations of atherectomy specimens from 
human coronary restenosis lesions have not demon- 
strated any significant ongoing SMC proliferation. 68 
Although these findings have been contradicted by 
others, 69'70 intimal hyperplasia nd SMC proliferation 
may only partly contribute to restenosis development 
in humans and alternative mechanisms have to be 
considered. 71"72 These include vascular remodeling 
and reorganisation of the vessel architecture, lesion 
angiogenesis and deposition of extracellular 
matr ix .  43'73"74 Without a consensus on the aetiology of 
restenosis, it is difficult to select the appropriate 
pathophysiological process and genes to target in a 
gene therapy approach. 5°'75 Gene therapy targeting 
other aspects of the disease than SMC proliferation 
appears more complex and the selection of alternative 
genes will require more experimental data. Despite 
these concerns, gene therapy may soon be tested in a 
post-angioplasty restenosis trial utilising the anti- 
proliferative approach. The results of such attempts 
should be interpreted with caution since a negative 
result may reflect the selection of an inappropriate 
target gene rather than a failure for the technology 
itself. 
Gene Therapy in the Treatment of Critical Lower 
Limb Ischaemia 
The management of lower limb ischaemia is a tempt- 
ing application of gene therapy. Theoretically, this 
could be achieved by inducing angiogenesis n col- 
lateral vessels or by improving microvasculatory flow. 
In both situations, gene transfer can be used to 
modulate EC function since these cells are easily 
accessed in the vasculature. 76Transfection of ECs can 
be accomplished by ex vivo gene transfer protocols, or 
by direct gene transfer to a capillary bed or to vascular 
segments. The former method has been used to 
transfect ECs with marker genes before seeding of the 
cells too a denuded vascular segmentY '77 Gene 
transfer to ECs in vivo has been accomplished by direct 
78 injection of DNA to skeletal muscle, by the use of 
double-balloon catheter delivery of liposomal vec- 
tors, 79 or by direct transfer of DNA from a hydrogel 
coated angioplasty balloon. 13 An alternative approach 
to modulate EC function is by transfecting other cell 
types ex vivo followed by implantation of these cells. 
This method has been used to obtain physiological 
levels of erythropoietin and growth hormone after 
retroviral ex vivo transfection of myoblasts and 
SMCs, 8°-82 but it has not yet been used as a method to 
promote angiogenesis. 
Induction of angiogenesis and enhancement of 
collateral vessel flow reduce symptoms in the skeletal 
muscle of patients with peripheral vascular occlusive 
disease, s3'84 This improvement ofblood flow probably 
involves both expansion of pre-existing vessels and 
growth of new vessels. The use of angiogenic growth 
factors either in recombinant form as drugs or in gene 
therapy constitutes an appealing new strategy in the 
62 management of critical ischaemia. The growth factor 
family first discussed in this context was FGF. 85 Nabel 
et al. noted neocapillary formation in the intima of 
porcine arterial segments transfected with aFGF and 
suggested that this gene could be used for gene 
therapy of critical ischaemia. 86 In addition, an 
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increased capillarity in different ischaemia models in 
animals after infusions of recombinant bFGF has been 
reported, 87'8s but no articles on the treatment of limb 
ischaemia using gene transfer of FGF have yet been 
published. Because FGF is not specific for ECs and 
affects many other cell types, it is probably not 
suitable for therapeutic angiogenesis. 42'86 
Another endogenous growth factor VEGF, that is 
more EC specific and potent than FGF, s9 is the most 
promising factor for therapeutic angiogenesis. Unlike 
FGF, the VEGF protein contains a secretory signal 
sequence which enhances the probability of secretion 
and biological effect. VEGF is reported to increase 
capillarity and limb blood flow in animal models of 
ischaemia. 9°-92 In one study this improvement was 
apparent after one single injection of the recombinant 
protein and was durable for at least 30 days. 93 
Increased proliferation of cultured rat ECs after 
transfection with a retroviral vector and adenoviral 
vector containing the VEGF gene has been 
reported. 94'95 The same two studies also demonstrated 
angiogenesis n mice after subcutaneous injection of 
the same vectors. 
In 1994, the FDA approved a clinical trial with the 
objectives of evaluating the safety of vascular gene 
transfer in humans and the use of gene transfer of 
VEGF to treat critical limb ischaemiaJ 3 Twenty-two 
non-diabetic patients with rest pain and/or ischaemic 
ulcers that are not considered for vascular econstruc- 
tion will be included in the study. The subjects will 
receive scalating doses of VEGF DNA inserted into a 
plasmid vector and transferred to the luminal endo- 
thelium of the profunda artery using a hydrogel- 
coated angioplasty balloon (see above). The gene is 
anticipated to be transcribed by the luminal endothe- 
lium and the protein secreted into the circulation to 
target ECs in collateral vessels downstream. Because 
of the poor transfer efficiency of the chosen mode of 
gene transfer, a low transfer efficiency and a transient 
expression of the gene can be expected, resulting in a 
local secretion of the VEGF protein at a low concentra- 
tion. Since single doses of VEGF have effectively 
induced angiogenesis in animal models, 93 this 
approach may be sufficient but it may also confuse the 
interpretation of a negative result of the study. 
The primary objective of the study is the safety of 
the treatment. Consequently, the patients will be 
followed for 12 months with a variety of radiological 
and laboratory tests designed to evaluate induction of 
tumour growth since VEGF may induce angiogenesis 
in subclinical tumours. 89'96 Clinical response to treat- 
ment is considered relief of rest pain and/or ulcer 
healing and the effect will be monitored objectively by 
pressure measurements, duplex scanning and angiog- 
raphy. Recently, promising preliminary results from 
the first seven patients was presented. In three 
patients, the highest approved ose of VEGF plasmid 
reduced the symptoms and increased limb blood-flow 
as demonstrated by MRA, conventional angiography 
and intravascular Doppler. 97 Undoubtedl)5 the final 
results of this trial will gather much attention and 
influence the directions of future attempts in this area. 
However, the interpretation of the results may require 
some caution. Although the end-points of the trial 
may give acceptable information on the effect of the 
therap3¢ objective determination of true vessel growth 
may be difficult. Increased capillarity may be due to 
opening of previously closed vessels and improve- 
ments in flow could be attributed to vasodilation. 
Genetic Engineering of Vascular Grafts 
Genetic manipulation of cells in vascular grafts aimed 
at preventing raft failure is perhaps the most promis- 
ing application of gene therapy in cardiovascular 
disease and was one of the first suggested applications 
of the method. In 1989, Wilson et al. reported the 
transplantation of canine ECs, retrovirally transfected 
with the marker gene beta-galactosidase, to Dacron 
grafts. 19 The grafts were interposed to the carotid 
artery of Mongrel dogs and examinations 5 weeks 
later showed an intact layer of ECs on the graft 
surface. Although a reduction in cells expressing the 
marker gene was noted, the application itself seemed 
feasible. Similar studies have shown an even greater 
loss of marker gene expression after exposure to 
flow, 9s'99 probably due to haemodynamic forces. 1°° 
Seeding of grafts with ECs over-expressing fibrinolytic 
factors such as tissue plasminogen activator (t-PA) has 
been proposed as an approach to decrease the pro- 
thrombotic properties of synthetic grafts, t-PA trans- 
fected ECs maintain a high secretion of t-PA under 
different flow conditions in vitroJ m ECs transfected 
with t-PA and urokinase were also shown to exert 
fibrinolytic activity in a baboon model with an 
arteriovenous shunt including a PTFE segment with 
seeded cells, m2 In contrast, grafts seeded with t-PA 
transfected ECs lost fibrinolytic activity after implan- 
tation into the arterial circulation of sheep. Here, the 
transduced ECs were lost from the graft surface, most 
likely due to excess plasmin activity promoting 
detachment of the cells. 1°3 Thus, many problems have 
to be solved in order to develop synthetic grafts coated 
with ECs genetically designed to prevent graft throm- 
bosis. Genes encoding other antithrombotic proteins 
have to be evaluated in suitable experimental models 
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and the appropriate biomaterials have to be devel- 
oped that allow the retention of seeded cells on the 
graft surface. 1°4 
In addition to experiments aimed at improving the 
performance of synthetic grafts, similar studies have 
been made with vein grafts 1°5"1°6 and stents 1°7 seeded 
with transfected ECs. 
Direct gene transfer of vein grafts has been used to 
inhibit the fibroproliferative r sponse of SMCs asso- 
ciated with stenosis and occlusion of bypass grafts. An 
antisense approach targeting the cell cycle regulatory 
proteins, proliferating cell nuclear antigen (PCNA) 
and cell division cycle 2 kinase (cdc-2-kinase), was 
used to treat vein grafts before reimplantation i the 
arterial circulation of rabbits. The treatment not only 
restricted the formation of a neointima in the grafts 
but also made them more resistant o an atherogenic 
diet. 1°8 Gene transfer has also been achieved in human 
saphenous vein ex vivo. 1°9 Thus, a gene therapy 
strategy could represent a promising approach to 
prevent graft failure if a suitable target gene can be 
selected and useful protocols for gene transfer of 
autologous conduits are developed9 4 
Future Perspectives 
We have discussed how gene therapy strategies may 
become treatment options in the management of 
restenosis, critical imb ischaemia, and graft failure. At 
present, the technology is primarily an experimental 
tool and its therapeutic potential in human vascular 
disease remains to be tested. It is reasonable to assume 
that the initial attempts to evaluate these strategies in 
vascular surgery will be multidiciplinary and involve 
both basic scientists and clinicians. Because many 
approaches to gene therapy in vascular surgery will 
ultimately depend on surgical or interventional proce- 
dures, vascular surgeons should be encouraged not 
only to follow, but also to actively participate in the 
development of this technology. 
So far, human gene therapy has been evaluated in 
the treatment of genetic disorders and cancer. In the 
former case, the results of two recently published 
reports suggests that a genetic defect (ADA; see 
above), can. be corrected, by gene transfer3 ~0 to leukocytes. 
ex wvo using a retrowral vector. ' Retrovlral trans- 
fection of liver cells have also been used to transfer the 
LDL-receptor gene in patients with familial hyper- 
cholesterolaemia ~11and adenoviral transfer was used 
in attempts to correct the genetic defect of patients 
with cystic fibrosis. 112 Although these attempts have 
demonstrated that gene transfer in humans can be 
achieved, with the possible xception of the ADA-trial, 
none have shown any clinical effect of the therapy. 
It is difficult to predict the immediate future for 
vascular gene therapy. As discussed above, we are 
faced with problems related to the technology itself 
such as the safety and efficacy of gene transfer using 
different protocols. In addition, we still need to learn 
more about the aetiology of many vascular disorders 
in order to select appropriate target genes and design 
adequate trials. Thus, the interpretation ofresults from 
vascular gene therapy trials as well as the design of 
new trials must be carefully undertaken in order to 
achieve the best evaluation of this technology. In spite 
of these concerns, the concept of gene therapy will 
probably be added to the therapeutic arsenal of 
vascular surgery and change fundamental aspects in 
the management of vascular disease. 
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